thalidomide has been researched along with Adenomatous Polyposis Coli in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Adenomatous Polyposis Coli: A polyposis syndrome due to an autosomal dominant mutation of the APC genes (GENES, APC) on CHROMOSOME 5. The syndrome is characterized by the development of hundreds of ADENOMATOUS POLYPS in the COLON and RECTUM of affected individuals by early adulthood.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In a heavily pretreated patient with advanced colorectal cancer carrying mutations in APC and KRAS genes, we show an early metabolic response and enhanced NK cell activity to monotherapy with lenalidomide." | 3.80 | Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy. ( Amann, A; Auer, T; Gamerith, G; Hilbe, W; Kircher, B; Loeffler-Ragg, J; Putzer, D; Schenk, B; Zwierzina, H, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gamerith, G | 1 |
| Auer, T | 1 |
| Amann, A | 1 |
| Putzer, D | 1 |
| Schenk, B | 1 |
| Kircher, B | 1 |
| Hilbe, W | 1 |
| Zwierzina, H | 1 |
| Loeffler-Ragg, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 1/2 Study of Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors[NCT01166035] | Phase 1/Phase 2 | 20 participants (Anticipated) | Interventional | 2010-03-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for thalidomide and Adenomatous Polyposis Coli
| Article | Year |
|---|---|
Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy.
Topics: Adenomatous Polyposis Coli; Adult; Angiogenesis Inhibitors; Antibody-Dependent Cell Cytotoxicity; An | 2014 |